Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Ensoma has raised $53.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2025.
Ensoma's investors include Bill & Melinda Gates Foundation, Cormorant Asset Management, Catalio Capital Management, RTW Investments, Gilead Sciences.
Ensoma is headquartered in Boston, United States.
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Ensoma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ensoma — Funding & Investors." VCBacked, September 22, 2025, https://www.vcbacked.co/company/ensoma. Accessed August 15, 2026.
VCBacked. (2025). Ensoma — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/ensoma
{{cite web |title=Ensoma — Funding & Investors |url=https://www.vcbacked.co/company/ensoma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated